5-溴-4-乙基嘧啶 | 951884-36-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-溴-4-乙基嘧啶
• 英文名称: 5-bromo-4-ethylpyrimidine
• CAS: 951884-36-9
• 化学式: C₆H₇BrN₂
• 分子量: 187.039
• InChiKey: MYEMCVSVGGPJRP-UHFFFAOYSA-N

物化性质

• 沸点：
  235.3±20.0 °C(Predicted)
• 密度：
  1.497±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-4-ethylpyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-4-ethylpyrimidine
CAS number: 951884-36-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7BrN2
Molecular weight: 187.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-4-乙基嘧啶 在 potassium phosphate 、 双氧水 、 palladium diacetate 、 甲基三氧化铼(VII) 作用下， 以 二氯甲烷 、 水 、 异丙醇 为溶剂， 反应 22.25h， 生成
  参考文献：
  名称：

  通过焓控制的亲核官能化对嘧啶进行 C2 选择性、官能团发散胺化

  摘要：

  杂芳胺的合成因其在小分子发现中的重要性而一直是有机化学中的一个重要课题。特别是，2-氨基嘧啶代表了一种在生物活性分子中普遍存在的高度特权结构基序，但通过直接功能化引入嘧啶 C2-N 键的一般策略是难以捉摸的。在这里，我们描述了一种用于位点选择性 C-H 官能化的合成平台，该平台提供嘧啶基亚胺盐中间体，然后可以原位转化为各种胺产物。基于机制的试剂设计允许嘧啶的 C2 选择性胺化，开辟了位点选择性杂芳基 C-H 官能化的新范围。

  DOI：

  10.1021/jacs.1c13373
• 作为产物：
  描述：

  5-bromo-4-chloro-6-ethylpyrimidine 在 对甲苯磺酰肼 、 sodium carbonate 作用下， 以 氯仿 为溶剂， 反应 18.0h， 以40%的产率得到5-溴-4-乙基嘧啶
  参考文献：
  名称：

  [EN] TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS DE TRIAZOLOPYRIDINE ET LEURS UTILISATIONS

  摘要：

  提供了一种具有公式（IA）的化合物，或其药用可接受的盐，已被证明可用于治疗PRC2介导的疾病或紊乱：其中A，R6，R7和R8如本文所定义。

  公开号：

  WO2017221092A1

文献信息

• NAPHTHYRIDINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282328A1

  公开（公告）日：2018-10-04

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• Combined Iron/Hydroxytriazole Dual Catalytic System for Site Selective Oxidation Adjacent to Azaheterocycles
  作者：Julian C. Cooper、Chaosheng Luo、Ryohei Kameyama、Jeffrey F. Van Humbeck

  DOI：10.1021/jacs.7b12864

  日期：2018.1.31

  This report details a new method for site-selective methylene oxidation adjacent to azaheterocycles. A dual catalysis approach, utilizing both an iron Lewis acid and an organic hydroxylamine catalyst, proved highly effective. We demonstrate that this method provides complementary selectivity to other known catalytic approaches and represents an improvement over current heterocycle-selective reactions

  本报告详细介绍了一种与氮杂杂环相邻的位点选择性亚甲基氧化的新方法。双催化方法，利用铁路易斯酸和有机羟胺催化剂，证明是非常有效的。我们证明该方法为其他已知的催化方法提供了互补的选择性，并代表了对目前依赖化学计量活化的杂环选择性反应的改进。
• [EN] INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS INDOLIN-2-ONE OU PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014202493A1

  公开（公告）日：2014-12-24

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar is a heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O; R1 is hydrogen, lower alkyl, halogen, amino, dimethylamino, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, CH(OH)CF3, (CH2)o-lower alkoxy, cycloalkyl optionally substituted by CF3, or heterocycloalkyl optionally substituted by lower alkyl; R2 is hydrogen, lower alkyl, (CH2)o-cycloalkyl, (CH2)o-O-cycloalkyl, (CH2)o-lower alkoxy, CH2)o-lower alkoxy substituted by halogen, (CH2)o-heterocycloalkyl optionally substituted by lower alkyl, (CH2)o-S(O)2-cycloalkyl, lower alkyl substituted by one or two hydroxy, lower alkyl substituted by one or two lower alkoxy, (CH2)o-S(O)2-lower alkyl, lower alkyl substituted by halogen or CH2CH(OH)CF3; R3 is halogen or lower alkyl; X is CH or N; X1 is CH or N; n is 1 or 2; o is 0, 1, 2 or 3; m is 0, 1 or 2; and the dotted line is a bond or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof The compounds may be used for the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.

  本发明涉及通式（I）中的2-氧代-2,3-二氢吲哚，其中Ar是一个杂环烃基，含有一个、两个或三个杂原子，选自N、S或O；R1是氢、低碳基、卤素、氨基、二甲胺基、氰基、被卤素取代的低碳基、被羟基取代的低碳基、CH(OH)CF3、（CH2）o-低碳醚、环烷基（可选地被CF3取代）、或杂环烷基（可选地被低碳基取代）；R2是氢、低碳基、（CH2）o-环烷基、（CH2）o-O-环烷基、（CH2）o-低碳醚、被卤素取代的（CH2）o-低碳醚、（CH2）o-杂环烷基（可选地被低碳基取代）、（CH2）o-S(O)2-环烷基、被一个或两个羟基取代的低碳基、被一个或两个低碳醚取代的低碳基、（CH2）o-S(O)2-低碳基、被卤素或CH2CH(OH)CF3取代的低碳基；R3是卤素或低碳基；X是CH或N；X1是CH或N；n是1或2；o是0、1、2或3；m是0、1或2；虚线是键或非键；以及其在药学上可接受的盐、消旋混合物、或其相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗某些中枢神经系统障碍，包括精神病（阳性和阴性症状）、精神分裂症、物质滥用、酒精和药物成瘾、强迫症、认知障碍、双相情感障碍、情绪障碍、重性抑郁症、治疗难治性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、睡眠障碍、慢性疲劳综合征、僵硬、关节炎的抗炎作用和平衡问题。
• A Convenient Late-Stage Fluorination of Pyridylic C−H Bonds with <i>N</i> -Fluorobenzenesulfonimide
  作者：Michael Meanwell、Matthew B. Nodwell、Rainer E. Martin、Robert Britton

  DOI：10.1002/anie.201606323

  日期：2016.10.10

  Pyridine features prominently in pharmaceuticals and drug leads, and methods to selectively manipulate pyridine basicity or metabolic stability are highly sought after. A robust, metal‐free direct fluorination of unactivated pyridylic C−H bonds was developed. This convenient reaction shows high functional‐group tolerance and offers complimentary selectivity to existing C−H fluorination strategies.

  吡啶在药物和药物线索中具有显着特征，因此人们强烈寻求选择性地控制吡啶碱度或代谢稳定性的方法。开发了一种坚固，无金属的未活化吡啶式CH键的直接氟化方法。这种方便的反应显示出很高的官能团耐受性，并为现有的CH氟化方法提供了互补的选择性。重要的是，这种后期吡啶基CH氟化为合理调节烷基吡啶药物的碱性，亲脂性和代谢稳定性提供了机会。
• [EN] PYRIDINE AND PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDINE ET DE PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017025523A1

  公开（公告）日：2017-02-16

  The present invention relates to compounds of formula (I) wherein R1' is CH3; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl or cyclopropyl; R3 is C1, F, CF3, cyano, methyl, methoxy or cyclopropyl; R4 is hydrogen, methyl or F; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

  本发明涉及化合物的公式(I)，其中R1'为CH3；R1为甲基、乙基、CF3、CH2OH、环丙基或氰基，或者R1'和R1可以共同形成1,1-二氧代四氢噻吩-3-基环；R2为氢、甲基、乙基、异丙基、叔丁基或环丙基；R3为C1、F、CF3、氰基、甲基、甲氧基或环丙基；R4为氢、甲基或F；X为N或CH；Y为N或CH；但X和Y不能同时为CH；或者其药学上可接受的盐或酸加成盐，或者其相应的外消旋体和/或光学异构体和/或立体异构体。公式I的化合物可用于治疗精神障碍，如精神分裂症、双相情感障碍、强迫症或自闭症谱系障碍。